OBJECTIVES: This multicenter, retrospective survey evaluated the efficacy and safety of @entity1749 retreatment in @entity1 with relapsed multiple @entity1582 who had responded to initial @entity1749 treatment. METHODS: Clinical records of 94 @entity1 receiving @entity1749 retreatment in Germany and Switzerland were reviewed. RESULTS: Sixty @entity1 were included according to prespecified criteria. @entity1 had received a mean 3.7    2.3 therapies prior to initial @entity1749 . Overall response rate to @entity1749 retreatment was 63.3%; 8 (13.3%), 3 (5.0%) and 27 (45.0%) @entity1 achieved complete response (CR), near-CR and partial response, respectively. Response to retreatment was associated with response to initial treatment (75.0% of @entity1 with CR to initial treatment responded to retreatment) and treatment-free interval (TFI) after initial treatment (76.9 vs. 38.1% overall response rate for @entity1 with TFI >6 vs.  <= 6 months). After retreatment, median time to progression was 9.3 months. Median TFI was 5.7 months; 31.7, 25.0 and 15.0% of @entity1 experienced a TFI longer than 6, 9 and 12 months, respectively. Reported adverse drug reactions were consistent with the known safety profile of @entity1749 and most resolved completely. CONCLUSIONS: These results demonstrate that relapsed multiple @entity1582 @entity1 who respond to initial @entity1749 treatment have a sustained susceptibility to @entity1749 and do not experience uncommon @entity137 to retreatment.

XXXX retreatment in relapsed multiple @entity1582 - results from a retrospective multicentre survey in Germany and Switzerland.

@entity1749 :: ('MESH:C400082', 'Chemical') :: ['bortezomib'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['myeloma'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']
@entity1749 :: (MESH:C400082,Chemical) :: ['Bortezomib']
